Published in final edited form as:

Am J Psychiatry. 2010 April ; 167(4): 381–386. doi:10.1176/appi.ajp.2009.08121886.

Teaching Trainees to Negotiate Research Collaborations With Industry: A Mentorship Model

David B. Merrill, M.D., Ragy R. Girgis, M.D., Lincoln C. Bickford, M.D., Ph.D., Stanislav R. Vorel, M.D., Ph.D., and Jeffrey A. Lieberman, M.D.

Department of Psychiatry, Columbia University, College of Physicians and Surgeons, and the Department of Psychiatry, New York State Psychiatric Institute, New York

Abstract

Research collaborations with the pharmaceutical industry can offer valuable opportunities for academic psychiatrists to gain access to important resources. Such relationships, however, often produce significant conflicts of interest, and recent attention has focused on the ways in which these conflicts can compromise research integrity. Psychiatric residents generally receive little education about industry-academia interactions. The authors report their experience collaborating on a research project with representatives of a pharmaceutical company, and they propose a model for teaching psychiatric trainees responsible and productive engagement with industry investigators.

Residents in a psychiatric training program were unsure about whether and how they would like to interact with the pharmaceutical industry. They had been cautioned by some faculty members about the potential for industry influence to bias their thinking and behavior, while other faculty had suggested that associations with industry are inevitable and, frequently, desirable. The majority of residents in the program began to interact with the pharmaceutical industry via attendance at industry-funded activities, acceptance of industry-sponsored gifts, awards, and medication samples, and reading of industry-financed journals and research studies. A smaller group of residents, finding it difficult to disentangle the tendentious elements of industry influence from useful ones, eschewed contact with the pharmaceutical industry whenever possible.

Those residents who were considering research careers found themselves facing a particular challenge. They valued the intellectual independence of academia but, in an era of increasing competition for limited research funds, regarded collaboration with the pharmaceutical industry as an opportunity to gain access to valuable resources: therapeutic compounds, data, expertise, and funding. They wished to make informed and deliberate choices about how to engage responsibly with industry but were sometimes uncertain about how to proceed.

Over the past decade, it has become increasingly apparent that interactions among physicians, academic medical centers, and the pharmaceutical industry are fraught with conflicts of interest that threaten the reputation of industry and academia as well as the ability of doctors to interpret data and treat patients without undue bias (1–3). For example,

Address correspondence and reprint requests to Dr. Merrill, M.D., Department of Psychiatry, College of Physicians and Surgeons, Columbia University, New York State Psychiatric Institute, 1051 Riverside Dr., New York, NY 10032; dm2172@columbia.edu..

Education in Psychiatry, like Treatment in Psychiatry, begins with a case vignette to illustrate an important problem in clinical psychiatry. However, the goal of Education in Psychiatry is to present and evaluate methods to teach students, trainees, and other psychiatrists how to treat patients with these problems.

a growing body of evidence shows that gifts from drug companies—ranging from food and pens to substantial stipends and honoraria—influence the choices that physicians make in treating their patients (1, 4–6).

In 2006, a joint task force of the American Board of Internal Medicine Foundation and the Institute on Medicine as a Profession published policy recommendations on conflicts of interest (7), and the Association of American Medical Colleges followed suit in 2008 (8). Both recommended strict guidelines, including a zero-dollar limit on all gifts (including food), restriction of interactions between industry representatives and physicians, centralized distribution of industry funds for continuing medical education, and discouragement of ghostwriting and speakers bureaus (1). Although there are no clear mechanisms for enforcing these recommendations, the institutions that have implemented them have generally found the transition smooth and rapid, with the effectiveness of “top-down” modeling of proper conduct being particularly effective (1). The current generation of residents and medical students may thus develop in a milieu where restraint and reflection in interactions with drug companies are the norm rather than the exception.

In the area of medical research, however, appropriate boundaries on interactions between academia and industry are less clear-cut, perhaps in part because this is a realm in which collaborations are more evidently mutually advantageous. Drug companies rely on medical centers to conduct trials and recruit patients, for thought leaders to design studies, and for academic scientists to identify new drug targets and test promising compounds. Complementarily, in an era of limited government funding, industry money is a much-needed boon to research activities in academic departments. In this context, industry-academia research collaborations have themselves become increasingly vulnerable to conflicts of interest. Whereas 20 years ago most academic investigators assumed complete responsibility for industry-sponsored studies, more recently the converse is true, with drug companies frequently exerting control over all aspects of the process, from designing experiments to analyzing data (sometimes even declining academic investigators access to their own data) to writing papers to dictating final decisions on which data to publish and where (2, 9). Studies are frequently designed and reported in ways that suit the interests of sponsoring companies, including over- or underdosing comparator compounds, choosing placebo-controlled trials over comparison with active competitor drugs, designating primary endpoints that are likely to favor the sponsor's product rather than the most clinically relevant outcomes, publishing partial data sets, and neglecting to publish negative results (2). An illustrative example involves recent revelations about studies by Merck on the cyclooxygenase-2 inhibitor rofecoxib that were ghostwritten by company employees despite attribution to academic investigators (10) or manipulated to underreport mortality caused by the drug (11). Similarly, a review of 74 clinical trials of antidepressant medications found that all but one of 38 positive studies were published, but only three of 36 negative studies were accurately represented (12).

It has been argued that major policy overhaul and increased oversight are needed in funding and publication processes for industry-sponsored research (13). Equally important may be a culture and policy shift within academic departments to prioritize ethical and transparent interactions with industry, much as is currently happening with drug company contributions to individual clinicians and educational programs (1, 3). A crucial point of intervention may be in the education of residents, who are in the process of learning to navigate relationships with industry.

“Teaching Trainees to Negotiate Research Collaborations With Industry”

Professor Jeffrey Lieberman, chair of the department in which the above-mentioned residents were training, informed the residents that he had been approached by

representatives of a pharmaceutical company who wished to collaborate on a research project. The company was interested in conducting a post hoc analysis of two large prospective trials to determine how its medication (aripiprazole) compared with a reference compound (haloperidol) in a subpopulation of patients with early-stage schizophrenia (14). Dr. Lieberman, as the faculty leader of the project, invited residents to become involved and offered to mentor them through the collaboration process.

Several residents volunteered to attend meetings in which Dr. Lieberman modeled collegiality and professional independence in his dealings with the pharmaceutical representatives. There was minimal interaction between the residents and the representatives when the chairman was not present (e.g., in the waiting room outside the conference room where the group met). After each meeting, Dr. Lieberman conferred with the residents and instructed them on responsible engagement with industry researchers. He emphasized the importance of careful review of the original trials (14) and subsequent analyses of the same trials (15–17) to determine what meaningful information might be obtained from a post hoc analysis; thoughtful selection of research hypotheses; and critical appraisal of results. Together, Dr. Lieberman and the residents framed several hypotheses of scientific and clinical interest and identified methods to test them using the company's data. They then submitted their hypotheses and proposed methods to the industry representatives for statistical analysis.

The nature of interactions between psychiatric trainees and the pharmaceutical industry is complex. Residents experience significant exposure to the industry in a variety of contexts (18–21), and many do not appreciate the potential consequences of resident-industry contacts (18, 22). For example, in many, but not all (23), studies, only a minority of residents reported believing that interactions with industry influence their prescribing practices (18, 21, 24–26), despite substantial evidence that information provided by drug companies to caregivers affects prescribing patterns (18). In fact, psychiatric residents may feel more immune to industry influence than do residents in other medical specialties (25).

Curiously, psychiatric training programs have placed little emphasis on educating residents about their contacts with industry. Until recently, most programs allowed unsupervised interactions between residents and industry representatives, and few had formal policies regulating these interactions (20, 21, 27, 28). While the majority of programs provide some instruction on resident-industry relationships, teaching in this area is generally informal (28) and tends to focus on the acceptance of gifts that may affect prescribing practices, to the neglect of other important relationships with industry (18), such as research collaborations. The lack of guidance and training on research collaborations with industry is regrettable, given the importance of exposing residents to research early in their training (29) and the considerable role that pharmaceutical companies play in research, particularly in the field of pharmacotherapy (30).

One explanation for the dearth of policy and education on interactions between residents and industry may be the lack of clarity regarding the efficacy of such interventions. A variety of educational and policy strategies targeting residents have been investigated, including in a psychiatric training program (25), with mixed results (22, 31–35). In one study, policies restricting contact between residents and drug companies were found to decrease the perceived benefit of these interactions (34). Some educational interventions have been shown to improve residents' understanding of the complexity of relationships with the pharmaceutical industry (22) or to lead residents to report greater caution when considering their future interactions with industry (31). One intervention, in contrast, succeeded only in educating residents about the negative effects that interactions with industry may have on

other physicians and did not persuade residents to reassess their own vulnerability to influence (32). Another strategy showed little impact on residents' opinions of industry (35). An educational intervention specifically targeting psychiatric residents resulted in decreased acceptance of gifts and supplies but did not appreciably alter attitudes about resident-industry interactions (25). In light of these conflicting data, further development and assessment of strategies for teaching residents how to understand and negotiate interactions with the pharmaceutical industry are merited (18, 20, 21, 24, 26, 27). Fortunately, there is substantial enthusiasm in the field of psychiatry, and among residents in particular, for more education in this area (25, 28).

Dr. Lieberman and the residents met with the industry representatives to review the results of the statistical analyses. The representatives' report included some of the analyses proposed by the departmental group and an outline for a manuscript that concluded that aripiprazole outperformed haloperidol in patients with early-stage schizophrenia. After careful inspection of the report, Dr. Lieberman and the residents found that the results did not, in fact, unequivocally support the company's conclusion. They noted that the mean dose of haloperidol used in the study was 8.6 mg/day, higher than that used in the most recent first-episode schizophrenia trials (36–38). Aware that early-stage schizophrenia patients are more sensitive to drug side effects and require lower doses of medications for therapeutic response (by 50% or more) than chronic patients (39–41) and that haloperidol in first-episode psychosis causes more extrapyramidal symptoms than do second-generation antipsychotics (36–38, 40, 42–44), the departmental group was prompted to consider whether the apparent superiority of aripiprazole may have been due predominantly to excessive dosing, and hence intolerable side effects, of haloperidol.

Dr. Lieberman and the residents worked with the industry representatives to obtain the complete results of the statistical analyses previously designated by the group (see Figure 1). These analyses revealed high rates of extrapyramidal symptoms and increased and more rapid dropout from the study among patients treated with haloperidol. Discontinuation due to an adverse event other than worsening illness was the only significant difference in reason for treatment discontinuation between treatments. In addition, the efficacy differences on the Positive and Negative Syndrome Scale (PANSS) favoring aripiprazole were seen in measures that could be confounded with extrapyramidal symptoms (45). Finally, when patients whose extrapyramidal symptoms were managed by dose reduction or the addition of anti-parkinsonian medication were examined separately, all PANSS efficacy differences disappeared.

Under the supervision of Dr. Lieberman, the trainees drafted a manuscript that reflected their interpretation of these results, including their impression that the difference in drug efficacy may have been secondary to the high dosage of haloperidol used in the study. This conclusion differed from publications of previous analyses of the parent trials, which found aripiprazole to be superior to haloperidol in durability of symptom response (14), adverse effects (14), remission rate (15), new-onset tardive dyskinesia rate (16), and utility (a function of PANSS scores and adverse effects) (17), with little (16, 17) or no (14, 15) mention of the possibility that the haloperidol dosage may have been excessive for patients early in the course of their illness.

While developing the manuscript, the residents continued to meet, with Dr. Lieberman and separately, to discuss the challenges of the project. These challenges included the selection of appropriate statistical methods for a post hoc analysis with multiple hypotheses; the difficulty and importance of prioritizing the

group's findings and interpretations, even when they differed from those of the pharmaceutical company; and the lack of transparency regarding the original data, to which the company retained exclusive access.

By the end of the project, the departmental group believed that they had identified findings of interest to clinical and research communities and that their presentation of these findings was objective and accurate. They had also learned about post hoc hypothesis formation, several statistical techniques, and the importance of access to original study data from the company.

Academic psychiatrists may benefit from research collaborations with industry (46), and the enterprise of industry-sponsored research may itself profit from the involvement of experienced academic investigators, as compared to exclusive reliance on researchers employed by the pharmaceutical industry. Few psychiatric training programs, however, provide instruction on how to negotiate these collaborations responsibly. We propose that the mentoring of trainees by a senior academic psychiatrist through a research project with industry representatives may be a useful means of teaching appropriate modes of working cooperatively with the pharmaceutical industry. Role modeling by senior psychiatrists has been reported to have a significant effect on the shaping of resident perceptions about industry in general (21, 35), and our experience suggests that the same may be true of research collaborations in particular.

In the proposed arrangement, the academician-trainee-industry relationship is analogous to the supervisor-resident-patient triad that forms the backbone of psychiatric education in many training programs. Such an approach benefits from the reciprocal advantages of allowing trainees to learn fruitful and principled modes of engaging industry researchers and motivating senior psychiatrists to model critical thinking, independence, and integrity in their dealings with the pharmaceutical industry. Notably, this approach also suffers from the same limitations as other supervisory relationships, especially those imposed by the mentor's own biases.

Despite recent consternation over academia-industry research collaborations, we believe that these cooperative efforts will remain legitimate and valuable opportunities for academic psychiatrists, if conducted responsibly. Given the limited government resources currently available for research and teaching and the increasing costs of large long-term clinical trials, psychiatric training programs may wish to embrace the expanding role of research collaborations with pharmaceutical companies and teach ethical and productive engagement with industry investigators. We suggest that the mentoring of trainees by a senior academic psychiatrist may be one effective way of doing this.

Acknowledgments

Drs. Merrill and Vorel have received research support from Janssen through the American Psychiatric Institute for Research and Education. Dr. Girgis has received research support from Janssen and Lilly through the American Psychiatric Institute for Research and Education and a travel stipend from Lilly, Forest, and Elsevier Science through the Society of Biological Psychiatry. Dr. Lieberman has received research support from or has served in an advisory or consulting capacity to Allon, AstraZeneca, Bioline, Bristol-Myers Squibb, Cephalon, Eli Lilly, Forest Laboratories, GlaxoSmithKline, Intracellular Therapies, Janssen, Merck, Otsuka, Pfizer, and Wyeth, served on a data safety monitoring board for Solvay, and holds a patent with Repligen. Drs. Bickford and Lieberman report no financial relationships with commercial interests.

The authors thank Dr. Itai Danovitch, whose thoughtful comments about industry-academia interactions informed this paper.

References

1. Rothman DJ, Chimonas S. New developments in managing physician-industry relationships. *JAMA*. 2008; 300:1067–1069. [PubMed: 18768417]
2. Angell M. Industry-sponsored clinical research: a broken system. *JAMA*. 2008; 300:1069–1071. [PubMed: 18768418]
3. Rellman AS. Industry support of medical education. *JAMA*. 2008; 300:1071–1073. [PubMed: 18768419]
4. Blumenthal D. Doctors and drug companies. *N Engl J Med*. 2004; 351:1885–1890. [PubMed: 15509823]
5. Dana J, Loewenstein G. A social science perspective on gifts to physicians from industry. *JAMA*. 2003; 290:252–255. [PubMed: 12851281]
6. Wazana A. Physicians and the pharmaceutical industry: is a gift ever just a gift? *JAMA*. 2000; 283:373–380. [PubMed: 10647801]
7. Brennan TA, Rothman DJ, Blank L, Blumenthal D, Chimonas SC, Cohen JJ, Goldman J, Kassirer JP, Kimball H, Naughton J, Smelser N. Health industry practices that create conflicts of interest: a policy proposal for academic medical centers. *JAMA*. 2006; 295:429–433. [PubMed: 16434633]
8. Association of American Medical Colleges. Industry Funding of Medical Education: Report of an AAMC Task Force. Washington, DC: Jun. 2008
https://services.aamc.org/Publications/show-file.cfm?file=version114.pdf&prd_id=232&prv_id=281&pdf_id=114
9. Steinbrook R. Gag clauses in clinical-trial agreements. *N Engl J Med*. 2005; 352:2160–2162. [PubMed: 15917381]
10. Ross JS, Hill KP, Egilman DS, Krumholz HM. Guest authorship and ghostwriting in publications related to rofecoxib: a case study of industry documents from rofecoxib litigation. *JAMA*. 2008; 299:1800–1812. [PubMed: 18413874]
11. Psaty BM, Kronmal RA. Reporting mortality findings in trials of rofecoxib for Alzheimer disease or cognitive impairment: a case study based on documents from rofecoxib litigation. *JAMA*. 2008; 299:1813–1817. [PubMed: 18413875]
12. Turner EH, Matthews AM, Linardatos E, Tell RA, Rosenthal R. Selective publication of antidepressant trials and its influence on apparent efficacy. *N Engl J Med*. 2008; 358:252–260. [PubMed: 18199864]
13. DeAngelis CD, Fontanarosa PB. Impugning the integrity of medical science: the adverse effects of industry influence. *JAMA*. 2008; 299:1833–1835. [PubMed: 18413880]
14. Kasper S, Lerman MN, McQuade RD, Saha A, Carson WH, Ali M, Archibald D, Ingenito G, Marcus R, Pigott T. Efficacy and safety of aripiprazole vs haloperidol for long-term maintenance treatment following acute relapse of schizophrenia. *Int J Neuropsychopharmacol*. 2003; 6:325–327. [PubMed: 14609439]
15. Kane JM, Crandall DT, Marcus RN, Eudicone J, Pikalov A, Carson WH, Swyzen W. Symptomatic remission in schizophrenia patients treated with aripiprazole or haloperidol for up to 52 weeks. *Schizophr Res*. 2007; 95:143–150. [PubMed: 17644313]
16. Miller DD, Eudicone JM, Pikalov A, Kim E. Comparative assessment of the incidence and severity of tardive dyskinesia in patients receiving aripiprazole or haloperidol for the treatment of schizophrenia: a post hoc analysis. *J Clin Psychiatry*. 2007; 68:1901–1906. [PubMed: 18162021]
17. Kane JM, Kim E, Kan HJ, Guo Z, Bates JA, Whitehead R, Pikalov A. Comparative utility of aripiprazole and haloperidol in schizophrenia: post hoc analysis of two 52-week, randomized, controlled trials. *Appl Health Econ Health Policy*. 2009; 7:109–119. [PubMed: 19731968]
18. Brodkey AC. The role of the pharmaceutical industry in teaching psychopharmacology: a growing problem. *Acad Psychiatry*. 2005; 29:222–229. [PubMed: 15937271]
19. Reeder M, Dougherty J, White LJ. Pharmaceutical representatives and emergency medicine residents: a national survey. *Ann Emerg Med*. 1993; 22:1593–1596. [PubMed: 8214843]
20. Sergeant MD, Hodgetts PG, Godwin M, Walker DM, McHenry P. Interactions with the pharmaceutical industry: a survey of family medicine residents in Ontario. *CMAJ*. 1996; 155:1243–1248. [PubMed: 8911290]

21. Zipkin DA, Steinman MA. Interactions between pharmaceutical representatives and doctors in training: a thematic review. *J Gen Intern Med.* 2005; 20:777–786. [PubMed: 16050893]
22. Watkins RS, Kimberly J Jr. What residents don't know about physician-pharmaceutical industry interactions. *Acad Med.* 2004; 79:432–437. [PubMed: 15107282]
23. Sigworth SK, Nettleman MD, Cohen GM. Pharmaceutical branding of resident physicians. *JAMA.* 2001; 286:1024–1025. [PubMed: 11559285]
24. Hodges B. Interactions with the pharmaceutical industry: experiences and attitudes of psychiatry residents, interns, and clerks. *CMAJ.* 1995; 153:553–559. [PubMed: 7641153]
25. Randall ML, Rosenbaum JR, Rohrbaugh RM, Rosenheck RA. Attitudes and behaviors of psychiatry residents toward pharmaceutical representatives before and after an educational intervention. *Acad Psychiatry.* 2005; 29:33–39. [PubMed: 15772402]
26. Steinman MA, Shlipak MG, McPhee SJ. Of principles and pens: attitudes and practices of medicine housestaff toward pharmaceutical industry promotions. *Am J Med.* 2001; 110:551–557. [PubMed: 11347622]
27. Mahood S, Zagozeski C, Bradel T, Lawrence K. Pharmaceutical policies in Canadian family medicine training: survey of residency programs. *Can Fam Physician.* 1997; 43:1947–1951. [PubMed: 9386881]
28. Varley CK, Jibson MD, McCarthy M, Benjamin S. A survey of the interactions between psychiatry residency programs and the pharmaceutical industry. *Acad Psychiatry.* 2005; 29:40–46. [PubMed: 15772403]
29. Gilbert AR, Tew JD Jr, Reynolds CF 3rd, Pincus HA, Ryan N, Nash K, Kupfer DJ. A developmental model for enhancing research training during psychiatry residency. *Acad Psychiatry.* 2006; 30:55–62. [PubMed: 16473996]
30. Perlis RH, Perlis CS, Wu Y, Hwang C, Joseph M, Nierenberg AA. Industry sponsorship and financial conflict of interest in the reporting of clinical trials in psychiatry. *Am J Psychiatry.* 2005; 162:1957–1960. [PubMed: 16199844]
31. Agrawal S, Saluja I, Kaczorowski J. A prospective before-and-after trial of an educational intervention about pharmaceutical marketing. *Acad Med.* 2004; 79:1046–1050. [PubMed: 15504769]
32. Hopper JA, Speece MW, Musial JL. Effects of an educational intervention on residents' knowledge and attitudes toward interactions with pharmaceutical representatives. *J Gen Intern Med.* 1997; 12:639–642. [PubMed: 9346461]
33. Kelcher S, Brownoff R, Meadows LM. Structured approach to pharmaceutical representatives: family medicine residency program. *Can Fam Physician.* 1998; 44:1053–1056. 1059–1060. [PubMed: 9612591]
34. McCormick BB, Tomlinson G, Brill-Edwards P, Detsky AS. Effect of restricting contact between pharmaceutical company representatives and internal medicine residents on post training attitudes and behavior. *JAMA.* 2001; 286:1994–1999. [PubMed: 11667936]
35. Schneider JA, Arora V, Kasza K, Van Harrison R, Humphrey H. Residents' perceptions over time of pharmaceutical industry interactions and gifts and the effect of an educational intervention. *Acad Med.* 2006; 81:595–602. [PubMed: 16799279]
36. Kahn RS, Fleischhacker WW, Boter H, Davidson M, Vergouwe Y, Keet IP, Gheorghe MD, Rybakowski JK, Galderisi S, Libiger J, Hummer M, Dollfus S, López-Ibor JJ, Hranov LG, Gaebel W, Peuskens J, Lindefors N, Riecher-Rössler A, Grobbee DE (EUFEST study group). Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomized clinical trial. *Lancet.* 2008; 371:1085–1097. [PubMed: 18374841]
37. Schooler N, Rabinowitz J, Davidson M, Emsley R, Harvey PD, Kopala L, McGorry PD, Van Hove I, Eerdekens M, Swyzen W, De Smedt G (Early Psychosis Global Working Group). Risperidone and haloperidol in first-episode psychosis: a long-term randomized trial. *Am J Psychiatry.* 2005; 162:947–953. [PubMed: 15863797]
38. Gaebel W, Riesbeck M, Wölwer W, Klimke A, Eickhoff M, von Wilmsdorff M, Jockers-Scherübl MC, Kühn KU, Lemke M, Bechdorf A, Bender S, Degner D, Schlösser R, Schmidt LG, Schmitt A, Jäger M, Buchkremer G, Falkai P, Klingberg S, Köpcke W, Maier W, Häfner H, Ohmann C, Salize HJ, Schneider F, Möller HJ (German Study Group on First-Episode Schizophrenia).

Maintenance treatment with risperidone or low-dose haloperidol in first-episode schizophrenia: 1-year results of a randomized controlled trial within the German Research Network on Schizophrenia. *J Clin Psychiatry*. 2007; 68:1763–1774. [PubMed: 18052570]

39. Chatterjee A, Chakos M, Koreen A, Geisler S, Sheitman B, Woerner M, Kane JM, Alvir J, Lieberman JA. Prevalence and clinical correlates of extrapyramidal signs and spontaneous dyskinesia in never-medicated schizophrenic patients. *Am J Psychiatry*. 1995; 152:1724–1729. [PubMed: 8526237]
40. Lieberman JA, Tollefson G, Tohen M, Green AI, Gur RE, Kahn R, McEvoy J, Perkins D, Sharma T, Zipursky R, Wei H, Hamer MM (HGDH Study Group). Comparative efficacy and safety of atypical and conventional antipsychotic drugs in first-episode psychosis: a randomized, double-blind trial of olanzapine versus haloperidol. *Am J Psychiatry*. 2003; 160:1396–1404. [PubMed: 12900300]
41. McEvoy JP, Hogarty GE, Steingard S. Optimal dose of neuroleptic in acute schizophrenia: a controlled study of the neuroleptic threshold and higher haloperidol dose. *Arch Gen Psychiatry*. 1991; 48:739–745. [PubMed: 1883257]
42. Crespo-Facorro B, Pérez-Iglesias R, Ramirez-Bonilla M, Martínez-García O, Llorca J, Vázquez-Barquero JL. A practical clinical trial comparing haloperidol, risperidone, and olanzapine for the acute treatment of first-episode nonaffective psychosis. *J Clin Psychiatry*. 2006; 67:1511–1521. [PubMed: 17107241]
43. Emsley RA. Risperidone in the treatment of first-episode psychotic patients: a double-blind multicenter study. *Schizophrenia Bull*. 1999; 25:721–729.
44. Green AI, Lieberman JA, Hamer RM, Glick ID, Gur ED, Kahn RS, McEvoy JP, Perkins DO, Rothschild AJ, Sharma T, Tohen MF, Woolson S, Zipursky RB (HGDH Study Group). Olanzapine and haloperidol in first episode psychosis: two-year data. *Schizophr Res*. 2006; 86:234–243. [PubMed: 16887334]
45. Miyamoto S, Duncan GE, Marx CE, Lieberman JA. Treatments for schizophrenia: a critical review of pharmacology and mechanisms of action of antipsychotic drugs. *Mol Psychiatry*. 2005; 10:79–104. [PubMed: 15289815]
46. Wasserstein AG, Brennan PJ, Rubenstein AH. Institutional leadership and faculty response: fostering professionalism at the University of Pennsylvania School of Medicine. *Acad Med*. 2007; 82:1049–1056. [PubMed: 17971690]

We conducted a post hoc analysis of two randomized double-blind 52-week multicenter trials. Participants were men and women 18 to 65 years of age with DSM-IV diagnoses of schizophrenia who were experiencing an acute relapse. Other inclusion criteria were previous response to antipsychotic medication, excluding clozapine. Exclusion criteria included a current first episode of schizophrenia and recent substance dependence. Early-stage patients were defined by duration of illness <5 years at time of enrollment and age at onset <40 years old. Patients were randomly assigned in a 2:1 ratio to receive aripiprazole (30 mg/day) or haloperidol (5 mg/day for 3 days, then 10 mg/day). The primary outcome measure was response defined as improvement $\geq 50\%$ in total score on the Positive and Negative Syndrome Scale (PANSS), without a Clinical Global Impressions improvement score of ≥ 6 , an adverse event of worsening schizophrenia, or a score ≥ 5 on any of the PANSS psychotic items for at least 28 consecutive days.

Of 1,294 patients in the parent trials, 360 were classified as early-stage patients and randomly assigned to receive aripiprazole (N=237) or haloperidol (N=123). The mean dose of aripiprazole was 28.4 mg/day (SD=3.1), and that of haloperidol was 8.6 mg/day (SD=1.2). The median period in treatment was 40 weeks (range, 8–52) for the aripiprazole group and 9 weeks (range, 3–52) for the haloperidol group ($p<0.001$). Patients taking haloperidol

were more likely to discontinue the study drug because of an adverse event other than worsening illness (29% compared with 11%, $p<0.01$). No other reason for discontinuation was significantly different between the two groups. Aripiprazole was associated with a significantly greater response rate than haloperidol (38% compared with 22%, $p<0.01$), while the time to achieve response did not differ significantly between groups (risk ratio=1.34, $p=0.18$). Patients receiving haloperidol experienced significantly more extrapyramidal symptoms than did those receiving aripiprazole (40% compared with 12%, $p<0.001$). Because of the disproportionate rates of extrapyramidal symptoms between treatments, which may affect clinical response, analyses examined the influence of dosage and adverse effects on therapeutic response. Aripiprazole remained superior to haloperidol for patients who continued at the target dosage and did not receive antiparkinsonian medication, as indicated by the change in PANSS total score (aripiprazole, -44.56 [SE=1.21], N=71; haloperidol, -35.46 [SE=2.19], N=17; $p<0.01$). For patients whose dose of either drug was reduced because of adverse effects, with or without the addition of antiparkinsonian medication, there were no longer significant differences in any PANSS total or subscale score changes (PANSS total score: aripiprazole, -43.99 [SE=2.22], N=23; haloperidol, -45.18 [SE=2.61], N=11; $p=0.73$).

FIGURE 1.
Analysis of Effects of Aripiprazole and Haloperidol in Early-Stage Schizophrenia